Table 3.

Differences, by UGT1A1^*28 genotype, in time from diagnosis, metastatic disease and treatment

	6/6	6/7	7/7	ALL (n=329)
	n=137	n=153	n=39
Time (in weeks) from initial diagnosis and treatment start (p=0.014)&
Median	62	39	42	48
Inter-quartile Range	22–122	11–86	11–97	13–109
Time (in weeks) from 1st metastasis/recurrence to treatment start (p=0.13)&
Median	13	11	13	12
Inter-quartile Range	6–38	5–23	8–38	6–30
Treatment protocol^ (p=0.69)
FOLFIRI	42%	37%	28%	38%
IFL	37%	44%	44%	41%
Other irinotecan-based (TEGAFIRI, XELIRI)	21%	19%	28%	21%

^*chi-Square test

^&Kruskal-Wallis test

^{^}In patients with genotype and full oncological follow-up